A Galapagos investor signals impatience with its turnaround efforts

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

And hello again! Miss us?

This morning STAT brings you an exclusive story about how the Biden administration’s program to develop antivirals for future pandemics has faltered. We also point out that gene-editing player Tome will lay off nearly all of its employees, and highlight a cautionary tale from Harvard’s Jeffrey Flier on dismissing promising technology too soon.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In